Skip to main content
Premium Trial:

Request an Annual Quote

454 Publishes Amplification Component of Proprietary Sequencing Technology

NEW YORK, Nov. 18 (GenomeWeb News) - CuraGen subsidiary 454 Life Sciences is offering a glimpse of one aspect of its next-generation sequencing technology, which has been under development - and under wraps - since 454's spin-out in 2000. The company said today that it has published its method to amplify genome fragments for sequencing in its massively parallel platform.

The paper, published in the journal Electrophoresis and titled "A massively parallel PicoTiterPlate based platform for discrete picoliter-scale polymerase chain reactions," describes the amplification component of the company's proprietary solid-phase sequencing technology.

In the paper, the authors demonstrate simultaneous PCR amplification of several hundred thousand discrete reactions in 454's PicoTiterPlate platform. The company said the platform uses microfluidic reaction wells, each with a volume of 75 picoliters, which should greatly speed sample pereparation times for large-scale sequencing projects.

Richard Begley, CEO of 454 Life Sciences, said that the company is preparing the product for commercialization in 2004.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.